Wells Fargo Upgrades Bruker on Further Restructuring, Clinical Market Plans | GenomeWeb

NEW YORK (GenomeWeb) – Wells Fargo Securities today upgraded shares of Bruker to an Outperform rating and increased the price range on its stock after a Bruker official said the company plans to further restructure its Chemical and Applied Markets division and grow its presence in the clinical market.

Analyst Tim Evans upgraded Bruker from a previous Market Perform rating and raised the price range on Bruker's shares to between $25 and $27 from an earlier range of $21 to $22.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.